- Home
- CLCO vs OLMA Comparison
CLCO vs OLMA Comparison
Compare CLCO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLCO
- OLMA
- Stock Information
- Founded
- CLCO 2018
- OLMA 2006
- Country
- CLCO United Kingdom
- OLMA United States
- Employees
- CLCO N/A
- OLMA N/A
- Industry
- CLCO
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- CLCO
- OLMA Health Care
- Exchange
- CLCO Nasdaq
- OLMA Nasdaq
- Market Cap
- CLCO 360.2M
- OLMA 378.9M
- IPO Year
- CLCO N/A
- OLMA 2020
- Fundamental
- Price
- CLCO $7.89
- OLMA $8.26
- Analyst Decision
- CLCO
- OLMA Strong Buy
- Analyst Count
- CLCO 0
- OLMA 5
- Target Price
- CLCO N/A
- OLMA $24.00
- AVG Volume (30 Days)
- CLCO 67.4K
- OLMA 1.1M
- Earning Date
- CLCO 08-28-2025
- OLMA 11-11-2025
- Dividend Yield
- CLCO 7.78%
- OLMA N/A
- EPS Growth
- CLCO N/A
- OLMA N/A
- EPS
- CLCO 1.04
- OLMA N/A
- Revenue
- CLCO $322,034,000.00
- OLMA N/A
- Revenue This Year
- CLCO $3.27
- OLMA N/A
- Revenue Next Year
- CLCO N/A
- OLMA N/A
- P/E Ratio
- CLCO $7.18
- OLMA N/A
- Revenue Growth
- CLCO N/A
- OLMA N/A
- 52 Week Low
- CLCO $4.51
- OLMA $2.86
- 52 Week High
- CLCO $11.71
- OLMA $13.93
- Technical
- Relative Strength Index (RSI)
- CLCO 56.01
- OLMA 68.86
- Support Level
- CLCO $7.58
- OLMA $7.66
- Resistance Level
- CLCO $8.10
- OLMA $8.40
- Average True Range (ATR)
- CLCO 0.22
- OLMA 0.69
- MACD
- CLCO -0.02
- OLMA 0.08
- Stochastic Oscillator
- CLCO 56.99
- OLMA 91.77
About CLCO Cool Company Ltd.
Cool Co Ltd is a LNG shipping company. The company is engaged in the acquisition, ownership, operation and chartering of liquefied natural gas (LNG) carriers (LNGCs), and the operation of third party fleets under management agreements. The company manages its business through a single operating and reporting segment, the LNG carrier market.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.